Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain information on efficacy and safety of SHR3824 with
metformin over 24 weeks and 52 weeks in metformin monotherapy poorly glycemic controlled
chinese Type 2 Diabetes. Efficacy and safety will be evaluated by comparing the effect of
SHR3824 with metformin to placebo with metformin when given in oral doses.